Sign inJoin waitlistJoin the waitlist

Gregory Vidal

Associate Professor · University of Tennessee College of Medicine

Credentials: · · · · · · ·

History

University of Tennessee College of Medicine
Present
University of Tennessee College of Medicine
Present

Hematology and Medical Oncology
Post Doctoral Fellowship/Instructor (Post-Doc), Stanford University School of Medicine. (August 2013 - July
2012–2015
Post Doctoral Fellowship/Instructor (Post-Doc), Stanford University School of Medicine. (August 2013 - July
2010–2012
Internal Medicine
Stanford Health Care
2008–2010
Medical School. (2006
Tulane University School of Medicine
2004–2008

Research

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
JAMA Oncology · 2019 · 468 citations
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone
The Journal of Cell Biology · 2004 · 217 citations
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells
Cancer Research · 2006 · 174 citations

LS
Lee Schwartzberg
30 papers
AP
Andrew Paladino
7 papers · 2 as a resident
AJ
Amit Jain
4 papers · 4 as a fellow
FH
Felicia Hare
3 papers · 2 as a fellow
HR
Harsha Ranganath
3 papers
JM
Janice Mullins
3 papers
PV
Poojitha Valasareddy
3 papers · 2 as a fellow
AB
Adam Brufsky
2 papers
Amina Chaudhry
2 papers · 2 as a fellow
Anthony Elias
2 papers
Antoinette Tan
2 papers
AV
Ari Vanderwalde
2 papers

Clinical trials

Niraparib and Dostarlimab in HRD Solid Tumors
Principal investigator · Unknown · Phase 2
West Cancer Center
2021–2025
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Principal investigator · Unknown · Phase 2
West Cancer Center
2019–2024
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Site PI · Recruiting · Phase 1
Stemline Therapeutics, Inc.
2024–2029
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2023–2033